Imprinted Contact Lenses for Ocular Administration of Antiviral Drugs.
antiviral drug
cornea penetration
drug-eluting contact lens
molecularly imprinted hydrogel
sclera penetration
sustained release
Journal
Polymers
ISSN: 2073-4360
Titre abrégé: Polymers (Basel)
Pays: Switzerland
ID NLM: 101545357
Informations de publication
Date de publication:
04 Sep 2020
04 Sep 2020
Historique:
received:
07
08
2020
revised:
27
08
2020
accepted:
02
09
2020
entrez:
9
9
2020
pubmed:
10
9
2020
medline:
10
9
2020
Statut:
epublish
Résumé
A variety of ocular diseases are caused by viruses, and most treatments rely on the use of systemic formulations and eye drops. The efficient ocular barriers that oppose antiviral drug penetration have prompted the development of improved topical delivery platforms. The aim was to design hydrogel contact lenses endowed with an affinity for acyclovir (ACV) and its prodrug valacyclovir (VACV), first-choice drugs against herpes simplex virus (HSV) ocular keratitis, and that can sustain the release of therapeutic doses during daily wearing. Functional monomers suitable for interaction with these drugs were screened using computational modeling. Imprinted and non-imprinted hydrogels were prepared with various contents in the functional monomer methacrylic acid (MAA) and characterized in terms of swelling, transmittance, mechanical properties, and ocular compatibility (hen's egg test on chorioallantoic membrane (HET-CAM) assay). The values were in the range typical of soft contact lenses. Compared to ACV, the capability to load VACV was remarkably higher due to stronger electrostatic interactions with MAA. The advantages of the imprinting technology were evidenced for VACV. Stability of VACV loading solution/hydrogels under steam heat sterilization and subsequent drug release was investigated. Permeability studies through bovine and porcine cornea and sclera of the drug released from the hydrogels revealed that VACV accumulates in the cornea and can easily cross the sclera, which may facilitate the treatment of both anterior and posterior eye segments diseases.
Identifiants
pubmed: 32899893
pii: polym12092026
doi: 10.3390/polym12092026
pmc: PMC7565425
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministerio de Economía, Industria y Competitividad, Gobierno de España
ID : SAF2017-83118-R
Organisme : Agencia Estatal de Investigación
ID : AEI
Organisme : Xunta de Galicia
ID : ED431C 2016/008
Organisme : Xunta de Galicia
ID : AEMAT ED431E 2018/08
Organisme : European Regional Development Fund
ID : FEDER
Références
J Antimicrob Chemother. 2001 Feb;47 Suppl T1:17-27
pubmed: 11160032
J Pharmacol Exp Ther. 2004 Mar;308(3):1138-47
pubmed: 14617696
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
Ophthalmic Physiol Opt. 2006 Jan;26(1):57-64
pubmed: 16390483
J Pharm Sci. 2015 Oct;104(10):3386-94
pubmed: 26094884
Expert Opin Drug Deliv. 2014 Oct;11(10):1647-60
pubmed: 24975820
Optom Vis Sci. 2016 Apr;93(4):377-86
pubmed: 26945177
Biomacromolecules. 2011 Mar 14;12(3):701-9
pubmed: 21314109
Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5601-8
pubmed: 19608530
Macromol Biosci. 2005 Aug 12;5(8):728-33
pubmed: 16082622
Pharm Res. 2006 Jan;23(1):121-30
pubmed: 16320002
Nucleic Acids Res. 2016 Jan 4;44(D1):D1202-13
pubmed: 26400175
Expert Opin Drug Deliv. 2010 Jun;7(6):765-80
pubmed: 20408742
Altern Lab Anim. 2011 Mar;39(1):37-53
pubmed: 21452913
Antiviral Res. 2004 Feb;61(2):73-81
pubmed: 14670580
Cont Lens Anterior Eye. 2004 Dec;27(4):177-91
pubmed: 16303541
Microbes Infect. 2018 Oct - Nov;20(9-10):526-530
pubmed: 29329934
Eur J Pharm Biopharm. 2018 Jan;122:126-136
pubmed: 29079419
Ophthalmology. 2017 Nov;124(11):1678-1689
pubmed: 28942073
Cont Lens Anterior Eye. 2017 Apr;40(2):70-81
pubmed: 27884616
Pharm Res. 2002 Aug;19(8):1194-202
pubmed: 12240946
AAPS PharmSciTech. 2017 Apr;18(3):884-894
pubmed: 27368921
Ther Deliv. 2013 Sep;4(9):1141-61
pubmed: 24024513
Anal Chim Acta. 2010 Feb 5;659(1-2):178-85
pubmed: 20103122
Mater Sci Eng C Mater Biol Appl. 2019 Dec;105:110092
pubmed: 31546391
Acta Biomater. 2019 Jan 15;84:49-62
pubmed: 30448434
Lancet. 2001 May 12;357(9267):1513-8
pubmed: 11377626
J Control Release. 2012 Feb 10;157(3):391-7
pubmed: 21982900
J Histotechnol. 2019 Dec;42(4):202-214
pubmed: 31680648
Open Ophthalmol J. 2012;6:110-24
pubmed: 23248737
J Cheminform. 2011 Oct 07;3:33
pubmed: 21982300
Viruses. 2018 Jul 06;10(7):
pubmed: 29986399
Prog Retin Eye Res. 2006 Jul;25(4):355-80
pubmed: 16807055
Pharmaceutics. 2020 Jul 26;12(8):
pubmed: 32722548
Front Microbiol. 2020 Feb 11;11:139
pubmed: 32117158
Int J Pharm. 2018 Dec 1;552(1-2):39-47
pubmed: 30253214
Anal Bioanal Chem. 2016 Sep;408(24):6845-56
pubmed: 27488280
Eur J Pharm Sci. 2012 Aug 30;47(1):131-8
pubmed: 22659372
Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4703-6
pubmed: 20393107
Clin Exp Ophthalmol. 2016 Dec;44(9):824-837
pubmed: 27273328
Microorganisms. 2019 Oct 10;7(10):
pubmed: 31658632
Acta Biomater. 2016 Sep 1;41:302-11
pubmed: 27221794
J Am Acad Dermatol. 2007 Nov;57(5):737-63; quiz 764-6
pubmed: 17939933
Int J Pharm. 2015 Nov 30;495(2):783-91
pubmed: 26343911
Invest Ophthalmol Vis Sci. 2014 Jul 15;55(8):4896-904
pubmed: 25028363
Cochrane Database Syst Rev. 2015 Jan 09;1:CD002898
pubmed: 25879115
Biomaterials. 2005 Apr;26(11):1293-8
pubmed: 15475059
Curr Opin Ophthalmol. 2018 Jul;29(4):340-346
pubmed: 29846207
J Pharm Biomed Anal. 1997 Nov;16(3):515-20
pubmed: 9589411